AG Leitung

Prof., PhD, Albert Osterhaus, DVM
Scientific head
Durchwahl +49 511 953-6140
Zu sehen ist Professor Osterhaus
© Prof. Dr. Albert D.M.E. Osterhaus

A.D.M.E. Osterhaus, Prof. Dr. DVM

Professor Osterhaus war bis zum 1. Juli 2014 Leiter der Abteilung für Virowissenschaften am Erasmus MC Rotterdam, ist derzeit Professor für Wildtiervirologie und Virusentdeckung an der Universität Utrecht und Direktor des Research Center for Emerging Infections & Zoonoses (RIZ) sowie Gastprofessor an der Tierärztlichen Hochschule Hannover. Er hat eine lange Erfolgsgeschichte als wissenschaftlicher Forscher und Principal Investigator zahlreicher großer wissenschaftlicher Projekte.

Zu den wichtigsten Errungenschaften zählen die Entdeckung von mehr als 40 neuen Viren von Menschen und Tieren (z. B. humanes Metapneumovirus, Coronaviren, Influenzaviren), die Aufklärung der Pathogenese schwerwiegender menschlicher und tierischer Virusinfektionen sowie die Entwicklung neuer Interventionsstrategien. Dies hat es Gesundheitsbehörden wie der WHO ermöglicht, Krankheitsausbrüche wie SARS und die Aviäre Influenza wirksam zu bekämpfen. 

Professor Osterhaus war Doktorvater für mehr als 60 Studierende und hält mehrere Schlüsselpatente. Er ist außerdem Autor von mehr als 1020 Artikeln in Fachzeitschriften, die zusammen mehr als 50.000 Mal zitiert wurden.
Vor allem ist Professor Osterhaus der festen Überzeugung, dass Wissenschaffende eine Rolle bei der Übersetzung ihres Wissens zum Nutzen und zum Schutz der Gesellschaft spielen müssen.

Patente & Mitarbeiten

Patente (Auswahl aus >30)

2012
MERS-CoV Rezeptor (ausstehend)
MERS-CoV (ausstehend)

2009
MVA-patent influenza (Anwendung)

2008
WO2008061939 Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu

2007
US2007087333 Method to detect antigen-specific cytolytic activity, Publication date: 2007-04-19

2005
WO 2005/080991 “Method to detect antigen-specific cytolytic activity”

2003
US 2004/0005544 (US Appl. # 10/371.122) “Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of heterologous antigenic sequences”.

2002
WO 2002/057302(# PCT/NL02/00040)“A virus causing respiratory tract illness in susceptible mammals” 01200213.5 “Human metapneumovirus” – national phase application

2001
US 2001/631966B1 in cooperation with Aventis Pasteur “Induction of rev and tat specific cytotoxic T- cells for prevention and treatment of human immunodeficiency virus (HIV)

1996
Patent in samenwerking met Pasteur Mérieux Connaught, betreffende "Induction of rev and tat specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection".

1992
Patent in samenwerking met Pitman Moore, betreffende "Deletion cleavage site of the FIV glycoprotein".
Patent in samenwerking met Pitman Moore, betreffende "Indentificatie, virus neutralization determinant of FIV".
Europees Patent nr. 92202032.6: "Monoclonal antibodies to HIV-1 gp120, cell lines producing them, preparations for passive immunotherapy, vaccines containing corresponding epitope structures and process of preparing these antibodies". (Date of submission: 3 July 1992).

NIH

2009
Animal Models of Infectious Diseases

2006
SARS

2000
Protective capacity of HIV early protein specific CTL

NGI

2009
FES 2009, research line viral infections   (k€ 1700)

2009
VIRGO II   (k€ 700)

2004
VIRGO - Genomics and respiratory viruses   (k€ 2300)

WHO

2002
Efficacy and Safety of a Tetravalent Dengue Vaccine in a Macaque Model   (k€ 140)

2001
Aerosol vaccination against measles   (k€ 120)

2000
Novel generations of measles vaccines   (k€ 100)

PI / Co-Investigator Clinical Trials

2012
PI in an MVA recombinant influenza phase I clinical trial (investigator initiated)

2006
PI in an autologous DC vaccination study in HIV infected humans (investigator initiated)

2000
Investigator in: a double blind, randomised, placebo-controlled study of RWJ 270201 for the treatment of influenza infections in asthmatic subjects.

1999
Investigator in: a double blind, randomised, placebo-controlled study of RWJ 270201 for the treatment of influenza infections in healthy subjects.
Investigator in: immunogenicity and tolerability of three dosages of an anti RSV vaccine, administered in an ambulant elderly adult population over 60 years old. 

1998
Principal Investigator in: a single center, single-blinded placebo- controlled study of a recombinant RSV vaccine in the treatment of severe lower respiratory tract infection.
Principal Investigator in: a double blind, randomised, placebo- controlled study of Ro 64-0796 (also known as GS 4104) in the treatment of influenza in children with chronic asthma.
Principal Investigator in: a double blind, randomised, placebo- controlled study of Ro 64-0796 (also known as GS 4104) used for the treatment of influenza infection.

1997
Principal Investigator in: a double blind, randomised, placebo- controlled study of Ro 64-0796 (also known as GS 4104) used for the prevention of clinical influenza post exposure.
Principal Investigator in: a randomised, double-blind study to determine the cell-mediated and humoral immunogenicity of two influenza ISCOM™ vaccines (type I and II) versus Fluvax® (inactivated influenza vaccine split virion) in young healthy adults.

1996
Principal Investigator in: a double-blind, randomised, placebo- controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic Influenza A and B viral infections in adolescents and adults.

1995
Principal Investigator in: a double-blind, randomised, placebo- controlled, multicentre parallel-group study to investigate the efficacy and safety of GG167 administered twice or four times a day for the treatment of Influenza A and B viral infections.

1994
Principal Investigator in: a double-blind, randomised, placebo- controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled and intranasal GG167 in the treatment of Influenza A and B viral infections.
Principal Investigator in: GMDP as adjuvant to Influvac subunit vaccine Immunogenicity and reactogenicity of adjuvant GMDP orally administered just prior to vaccination with a trivalent influenza subunit vaccine. A double-blind placebo controlled study in nursing home residents.

Identikation von neu-auftretenden viralen Pathogenen in Menschen und Tieren

Liste der identifizierten Pathogene

2014

  • Identification of python torovirus

2013

  • Identification of human cyclovirus
  • Identification of seal parvovirus
  • Identification of fox HEV

2012

  • Identification of coronavirus as primary cause of MERS (MERS-CoV)
  • Identification of boa arenavirus
  • Identification of human calicivirus

2011

  • Influenza A (H1N1) virus in dogs
  • Identification of stone marten anellovirus
  • Identification of porcine picobirnavirus
  • Identification of ferret heptatitis E virus (HEV)
  • Identification of ferret coronavirus

2010

  • Identification of human picobirnavirus
  • Identification of human astrovirus

2009

  • Identification of deer astrovirus

2006

  • Identification of  dolphin herpesvirus

2005

  • Identification of H16 influenza A viruses in black headed gulls

2004

  • Identification of fourth human coronavirus

2003

  • Identification of influenza A (H7N7) virus in humans
  • Identification of coronavirus as the primary cause of SARS (SARS-CoV)

2002

  • Presence of hantavirus infection in Barbados
  • Presence of hantavirus infection in Indonesia
  • Identification of re-emerging PDV in Europe

2000

  • Identification of human metapneumovirus (hMPV) as a new member of the genus Metapneumovirus Identification of measles virus re-introduction in The Netherlands

1999

  • Identification of influenza B virus in seals

1998

  • Identification of a lentivirus from Talapoin monkeys (SIVtal)

1997

  • Identification of influenza A (H5N1) virus in humans
  • Identification of monk seal morbilliviruses (MSMV-WA/G)

1996

  • Identification of a g-herpesvirus in seals (phocid herpesvirus-2)

1995

  • Identification of CDV as cause of mass mortality in Serengeti lions
  • Hepatitis B virus infection in heart transplant patients in the Dijkzigt Hospital Rotterdam

1994

  • Parapoxvirus in grey seals

1992

  • Rhabdovirus of dolphins
  • Porpoise and dolphin morbilliviruses causing mortality in cetacean species

1990

  • First Orthopoxvirus in seals (affected by PDV infection)

1989

  • First demonstration of Hantavirus infections in humans and rodents in The Netherlands

1988

  • First picornavirus in seals (affected by PDV infection)
  • First phocid morbillivirus (phocid distemper virus, PDV): cause of mass mortality in seals

1984

  • First phocid herpesvirus (phocid herpesvirus 1): high mortality in young seals

1981

  • First demonstration of mouse pox in The Netherlands

1978

  • First demonstration of canine parvovirus in The Netherlands

1977

  • First non mammalian papillomavirus: Finch papilloma virus

Auszeichnungen

2012
WSAVA Global One Health Award

2010
ESCMID Award for Excellence in Clinical Microbiology and Infectious Diseases

2008
Erasmus Award, Erasmus MC Rotterdam, The Netherlands

2007
Allan Granoff Lectureship in Virology Award, St. Jude's Hospital
Prix scientifique Louis D - Académie des sciences de l’Institut de France -  research done in the field of transmissible diseases from man to animals, anthropozoonoses.

2006
European Respiratory Society  - European Lung Foundation Award - recognition of the contribution to the public lung health in Europe
Federa prize – for original and exceptional research achievements

2004
Reinier de Graaf medal – for exceptional contribution to medicine
Dr. Saal van Zwanenberg-Oragon prize for exceptional achievement in promoting scientific research
James H. Nakano Citation - CDC prize for exceptional scientific publications.

2003
Commander in the Order of the Dutch Lion - Royal decoration 

2002
The ESCV Gardner Lecture - Viruses emerging from animal reservoirs

2000
Mulder-Masurel Award on influenza research
UK Royal Society invited lecture on Catastrophes after crossing species barriers

1998
M.W.Beijerinck Virology Award, Royal Dutch Academy of Sciences

1995
Firkin Oration, Australian Society for Medical Research

1993
Laureate Van Loghem lecture, Dutch Society for Immunology

1992
Ciba Geigy Prize for Research in Animal Health

1989
Heine Medin Award: European Society against Virus Diseases

1985
Schimmel Viruly Award: Faculty of Veterinary Medicine, Utrecht

weitere Beschäftigte

Prajeeth Chittappen, Kandiyil, PhD
Wissenschaftlicher Mitarbeiter
Durchwahl +49 511 953-6138

Dr. Martin Ludlow

Projektleiter Molekulare Virologie

Durchwahl   +49 511 953-6112

martin.ludlow@tiho-hannover.de

Projekte:  
VIPER Projekleiter: Identifizierung wirtsspezifischer und viraler Faktoren bei der Übertragung des Hundestaupevirus zwischen verschiedenen Tierarten

zu sehen ist Martin Ludlow
© Martin Ludlow

Mariana González Hernández, PhD

Wissenschaftliche Mitarbeiterin (Postdoc)

Durchwahl   +49 511 953-6112

Mariana.Gonzalez.Hernandez(at)tiho-hannover.de

zu sehen ist Mariana Gonzalez Hernandez
© Mariana Gonzalez Hernandez

Franziska Geiselhardt

Tierärztin, PhD Studentin

Durchwahl   +49 511 953-6145

Franziska.Geiselhardt(at)tiho-hannover.de

Projekte:
Identifizierung von Wirts- und Virusdeterminanten der interspeziesischen Übertragung des Hundestaupevirus, VIPER

zu sehen ist Franziska Geiselhardt
© Franziska Geiselhardt

Sonja Jesse

Tierärztin, PhD Studentin

Durchwahl   +49 511 953-6145

sonja.tatjana.jesse(at)tiho-hannover.de

Projekte:
Metapneumovirus, Virus Discovery, VIPER

zu sehen ist Sonja Jesse
© Sonja Jesse

Dr. med. vet. Franziska Kaiser

Tierärztin, PhD Studentin

Durchwahl   +49 511 953-6145

franziska.kaiser(at)tiho-hannover.de

Projekte:
Charakterisierung ausgewählter Viren, die in Wildtierreservoirs identifiziert wurden, und Bewertung ihres Risikos für Haustiere und Menschen, SARS-CoV-2, VIPER

Monica Mirolo, M.Sc.

PhD Studentin

Durchwahl   +49 511 953-6145

Monica.Mirolo(at)tiho-hannover.de

Projekte:
Virus Discovery, Erinaceus coronavirus 1

zu sehen ist Monica Mirolo
© Monica Mirolo

Alina Schadenhofer

Tierärztin, PhD Studentin

Durchwahl   +49 511 953-6145

Alina.Schadenhofer(at)tiho-hannover.de

Projekte:
Respiratory Syncytial Virus, VIPER, R2N

Kristin Laudeley

MTA

Durchwahl   +49 511 953-6125

Kristin.Laudeley(at)tiho-hannover.de

Projekte:
Virus Discovery, SARS-CoV-2